Clostridium butyricum inhibits epithelial–mesenchymal transition of intestinal carcinogenesis through downregulating METTL3
暂无分享,去创建一个
Bangmao Wang | Danfeng Chen | Tianyu Liu | H. Cao | Wanru Zhang | Weilong Zhong | Xin Wang | Kexin Zhang | Ying Ding | Yue Dong | Mengfan Li
[1] Yang Zhao,et al. METTL3-mediated Hsa_circ_0000390 downregulation enhances the proliferation, migration, and invasion of colorectal cancer cells by increasing Notch1 expression , 2023, Human Cell.
[2] Sachin Aryal,et al. Faecalibacterium prausnitzii Attenuates CKD via Butyrate-Renal GPR43 Axis , 2022, Circulation research.
[3] T. Hirayama,et al. Iron accelerates Fusobacterium nucleatum–induced CCL8 expression in macrophages and is associated with colorectal cancer progression , 2022, JCI insight.
[4] Shukui Wang,et al. METTL3 dual regulation of the stability of LINC00662 and VEGFA RNAs promotes colorectal cancer angiogenesis , 2022, Discover Oncology.
[5] N. Forbes. Endoscopist Adenoma Detection Rates and their Correlation with Post-colonoscopy Colorectal Cancer. , 2022, Gastroenterology.
[6] Xiaona Lu,et al. Fusobacterium nucleatum induces excess methyltransferase‐like 3‐mediated microRNA‐4717‐3p maturation to promote colorectal cancer cell proliferation , 2022, Cancer science.
[7] Xinxiang Li,et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer , 2022, Gut.
[8] Zhigang Guo,et al. METTL3 antagonizes 5-FU chemotherapy and confers drug resistance in colorectal carcinoma , 2022, International journal of oncology.
[9] Zhujun Zhang,et al. Long non-coding RNA EVADR induced by Fusobacterium nucleatum infection promotes colorectal cancer metastasis. , 2022, Cell reports.
[10] Shiyu Tao,et al. Clostridium butyricum and Its Derived Extracellular Vesicles Modulate Gut Homeostasis and Ameliorate Acute Experimental Colitis , 2022, Microbiology spectrum.
[11] Bing Zhou,et al. Clostridium butyricum, a butyrate-producing potential probiotic, alleviates experimental colitis through epidermal growth factor receptor activation. , 2022, Food & function.
[12] Xiaoting Zhang,et al. METTL3 inhibits anti-tumor immunity by targeting m6A-BHLHE41-CXCL1/CXCR2 axis to promote colorectal cancer. , 2022, Gastroenterology.
[13] Zhixian Liu,et al. METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner. , 2022, Biochemical and biophysical research communications.
[14] J. Tabernero,et al. Clinical management of metastatic colorectal cancer in the era of precision medicine , 2022, CA: a cancer journal for clinicians.
[15] W. Yuan,et al. Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway , 2022, Annals of translational medicine.
[16] T. Yeatman,et al. Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression , 2022, Molecular cancer.
[17] Tianhua Zhou,et al. Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis , 2022, Nature Communications.
[18] Hao Wang,et al. Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells. , 2022, Molecular cell.
[19] G. Mazzoccoli,et al. Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism , 2022, Cell Death & Differentiation.
[20] Connor T. Skennerton,et al. Increased circulating butyrate and ursodeoxycholate during probiotic intervention in humans with type 2 diabetes , 2022, BMC microbiology.
[21] C. Bracken,et al. The many regulators of epithelial−mesenchymal transition , 2021, Nature Reviews Molecular Cell Biology.
[22] H. He,et al. N6-methyladenosine reader YTHDF1 promotes ARHGEF2 translation and RhoA signaling in colorectal cancer. , 2021, Gastroenterology.
[23] Bangmao Wang,et al. Microbial metabolite deoxycholic acid promotes vasculogenic mimicry formation in intestinal carcinogenesis , 2021, Cancer science.
[24] M. He,et al. N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer , 2021, Journal of Hematology & Oncology.
[25] Yuqi Luo,et al. Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC , 2021, Cancer cell international.
[26] guohua zhao,et al. N6-Methyladenosine Modification of PTTG3P Contributes to Colorectal Cancer Proliferation via YAP1 , 2021, Frontiers in Oncology.
[27] Chandler D. Gatenbee,et al. Immunosuppressive niche engineering at the onset of human colorectal cancer , 2021, Nature Communications.
[28] David R. Jones,et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients , 2021, Cell.
[29] P. Lan,et al. Cyr61 from adipose‐derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin αVβ5 , 2021, Molecular oncology.
[30] W. Yuan,et al. N6-methyladenosine-induced circ1662 promotes metastasis of colorectal cancer by accelerating YAP1 nuclear localization , 2021, Theranostics.
[31] Dan Zhou,et al. METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5 , 2021, Molecular oncology.
[32] Zhenghuan Fang,et al. Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690 , 2021, Bioengineered.
[33] Paul J. McMurdie,et al. Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease , 2021, Gut microbes.
[34] Shi-Ying Huang,et al. Evodiamine inhibits vasculogenic mimicry in HCT116 cells by suppressing hypoxia-inducible factor 1-alpha-mediated angiogenesis. , 2020, Anti-cancer drugs.
[35] Lanjuan Li,et al. The Intestinal Microbiota and Colorectal Cancer , 2020, Frontiers in Immunology.
[36] Jun Yu,et al. RNA m6A methyltransferase METTL3 facilitates colorectal cancer by activating m6A-GLUT1-mTORC1 axis and is a therapeutic target. , 2020, Gastroenterology.
[37] Wanshun Liu,et al. miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells , 2020, Frontiers in Cell and Developmental Biology.
[38] Yu Fang,et al. Prebiotics‐Encapsulated Probiotic Spores Regulate Gut Microbiota and Suppress Colon Cancer , 2020, Advanced materials.
[39] Fengqin Wang,et al. Enterotoxigenic Escherichia coli infection promotes enteric defensin expression via FOXO6-METTL3-m6A-GPR161 signalling axis , 2020, RNA biology.
[40] Hongchuan Jin,et al. β-catenin represses miR455-3p to stimulate m6A modification of HSF1 mRNA and promote its translation in colorectal cancer , 2020, Molecular Cancer.
[41] X. Wan,et al. Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice. , 2020, International immunopharmacology.
[42] Wenqi Wang,et al. Sodium Butyrate Selectively Kills Cancer Cells and Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1 , 2020, OncoTargets and therapy.
[43] Raymond B. Runyan,et al. Guidelines and definitions for research on epithelial–mesenchymal transition , 2020, Nature Reviews Molecular Cell Biology.
[44] Jie Hong,et al. m6A-dependent glycolysis enhances colorectal cancer progression , 2020, Molecular Cancer.
[45] K. Rhee,et al. Effect of Probiotic Clostridium butyricum NCTC 7423 Supernatant on Biofilm Formation and Gene Expression of Bacteroides fragilis , 2020, Journal of microbiology and biotechnology.
[46] Bangmao Wang,et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. , 2019, Cancer letters.
[47] Jun Yu,et al. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications , 2019, Nature Reviews Gastroenterology & Hepatology.
[48] Yueming Sun,et al. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway , 2019, Journal of Experimental & Clinical Cancer Research.
[49] D. Zheng,et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy , 2019, Nature Biomedical Engineering.
[50] D. Lin,et al. METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma , 2019, Molecular Cancer.
[51] A. Newton,et al. Apical-basal polarity inhibits Epithelial-Mesenchymal Transition and tumour metastasis via PAR complex-mediated SNAI1 degradation , 2019, Nature Cell Biology.
[52] T. Kawano,et al. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer , 2019, Molecular Cancer.
[53] Patrice D. Cani,et al. Gut cell metabolism shapes the microbiome , 2017, Science.
[54] J. Liu,et al. Clostridium butyricum partially regulates the development of colitis-associated cancer through miR-200c. , 2017, Cellular and molecular biology.
[55] Jing Yang,et al. Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.